SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Rhea-AI Summary
SCIENTURE (NASDAQ: SCNX) announced a strategic collaboration with BlinkRx to expand national access to Arbli™, the first FDA-approved ready-to-use oral suspension of losartan potassium. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026. The U.S. losartan market totals about $245M in annual sales with roughly 71 million prescriptions (IQVIA MAT Sept 2025). BlinkRx reports it helps 52% more patients start therapy and keeps them on medication 40% longer, which Scienture says may increase starts, duration, and affordability for patients needing suspension formulations.
Positive
- Arbli FDA-approved ready-to-use losartan suspension
- Expected Q1 2026 availability on BlinkRx platform
- Targets a U.S. losartan market of $245M and 71M prescriptions
- BlinkRx reports 52% more therapy starts and 40% longer persistence
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Down
Peers show mixed moves (e.g., SSY up 9.31%, HKPD down 3.1%, PETS down 0.62%), suggesting today’s SCNX move is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Investor conference | Neutral | +0.1% | Participation in virtual Best Ideas conference with webcast and investor meetings. |
| Nov 13 | Earnings and update | Positive | -5.5% | Q3 revenue and gross profit growth tied to Arbli launch and debt reduction. |
| Nov 04 | Formulary expansion | Positive | +15.3% | Arbli added to national payor formularies covering over 100M U.S. lives. |
| Oct 23 | Commercial sales start | Positive | +354.9% | Start of commercial sales and first orders for Arbli oral suspension. |
| Oct 16 | Wholesaler availability | Positive | -17.6% | Arbli becomes available through major U.S. wholesalers for liquid losartan. |
Recent Arbli-related positives have produced volatile and sometimes divergent reactions, with both sharp rallies and notable selloffs on broadly constructive news.
Over the last few months, SCIENTURE has repeatedly highlighted commercialization of Arbli™, the first FDA-approved ready-to-use losartan suspension, including launch, wholesaler availability, and major formulary/GPO access reaching >100 million lives and >2,500 institutions. These milestones have triggered both very large gains (up to +354.94%) and sharp pullbacks (down to -17.63%) within 24 hours. The latest collaboration with BlinkRx continues this commercialization and access theme for Arbli in the large U.S. losartan market.
Regulatory & Risk Context
SCNX has an active S-3 shelf filed on 2025-08-01 with multiple 424B5 takedowns, indicating capacity and intent to raise additional equity capital under this registration over time.
Market Pulse Summary
This announcement extends SCIENTURE’s Arbli™ commercialization push through a BlinkRx collaboration aimed at the U.S. losartan market of $245M and 71M prescriptions annually. BlinkRx’s platform data, with 52% more patients starting therapy and 40% longer persistence, underscores the access focus. Historically, Arbli milestones have produced both sharp rallies and selloffs, while recent filings describe an at-the-market program of up to $150,000,000 of common stock and an active S-3 shelf, factors that can influence future dilution and capital flexibility.
Key Terms
FDA-approved regulatory
AI-generated analysis. Not financial advice.
U.S. Losartan market totals
COMMACK, NY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, and Blink Rx LLC (“BlinkRx”), one of the most advanced patient access platforms for branded medications, today announced a strategic collaboration to expand national access to Arbli™, the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Arbli™ is expected to be available on the BlinkRx platform in Q1 2026.
BlinkRx holistically orchestrates and automates patient access, support, and delivery across the entire prescription journey. Its platform not only improves accessibility but also elevates the patient experience and drives meaningful health outcomes. With BlinkRx,
According to IQVIA data (MAT September 2025), the U.S. losartan market totals approximately
“Arbli™ represents a meaningful advancement for patients who need a ready-to-use oral suspension of losartan potassium,” commented Narasimhan Mani, President and co-CEO of Scienture. “BlinkRx removes friction in the patient journey, from reducing administrative barriers and accelerating therapy initiation to improving adherence, which translates into greater prescription volume, longer duration on therapy, lower access costs, and broader patient affordability and reach.”
“This collaboration reflects our shared commitment to affordability, access, and sustained therapeutic benefit,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “Our goal has always been to deliver accessible, patient-centric therapies. Partnering with BlinkRx ensures that more people can start treatment without unnecessary delays or barriers.”
Geoffrey Chaiken, CEO of Blink Health, Inc., the parent company of BlinkRx, added, “We are proud to support Scienture in expanding access to Arbli™. Losartan is widely prescribed across the U.S. and offering a ready-to-use oral suspension helps meet an important medical need. BlinkRx’s platform will ensure patients can start therapy sooner, stay supported throughout treatment, and experience improved outcomes.”
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).
- Do not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence ≥
2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
About BlinkRx
BlinkRx is revolutionizing the pharmacy experience, using cutting-edge technology to dramatically improve patient access for branded medications. Health care providers benefit from dedicated access teams and streamlined prior authorization support for patients. Patients enjoy affordable, transparent pricing, co-pay assistance, free home delivery, and personalized support.
Learn more at www.blinkrx.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
BlinkRx Contacts
BlinkRx Media Contact:
Dan Dantus
dan.dantus@blinkrx.com
www.blinkrx.com
Blink Health LinkedIn
FAQ
When will Arbli™ be available on BlinkRx for SCIENTURE (SCNX)?
What is Arbli™ and why is it important for patients using losartan (SCNX)?
How large is the U.S. losartan market cited in the SCNX announcement?
How might the BlinkRx collaboration affect SCNX patient starts and adherence?
What is the strategic purpose of the SCIENTURE and BlinkRx collaboration for SCNX shareholders?
